Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022737 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
A Phase 3 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia in Remission, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT00022737: Completed Phase 3 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia in Remission, sponsored by National Cancer Institute (NCI).
NCT00022737 is a Phase 3 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia in Remission that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 220 participants, above the 107-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (106% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00022737, a Phase 3 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Childhood Acute Lymphoblastic Leukemia in Remission, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Primary Outcome
As a target goal, we wish to enroll at least 80% of the potential available patients. The accrual duration for this pilot study will be based on accruing adequate numbers to complete the dose escalation study in the Ph+ subset. The planned study accrual duration should be approximately 1.75 years.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG cyclosporine
- DRUG asparaginase
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2002-10 |
| Phase | Phase 3 |
What the finished NCT00022737 record still lists
NCT00022737 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (106% higher).
The record links to 2 conditions, with Recurrent Childhood Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00022737 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00022737 about?
NCT00022737 is a clinical study titled "Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia". This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. ...
What is the current status of trial NCT00022737?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2002-10.
What conditions does trial NCT00022737 study?
This clinical trial studies the following conditions: Recurrent Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission.
What interventions are being tested in trial NCT00022737?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), cyclosporine (DRUG), asparaginase (DRUG).
Who is sponsoring clinical trial NCT00022737?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022737 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00022737's enrollment target sits among peer trials
220 2nd of 11 the highest of 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Childhood Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
COMPLETED · Phase 3
-
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
RECRUITING · Phase 1
-
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ACTIVE NOT RECRUITING · Phase 2
-
DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia